Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation

LESSONS LEARNED: Cediranib and olaparib combination did not result in clinically meaningful activity in patients with metastatic pancreatic ductal adenocarcinoma without known BRCA mutation. BACKGROUND: Cediranib, a vascular endothelial growth factor receptor inhibitor, suppresses expression of BRCA...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncologist
Glavni autori: Kim, Joseph W., Cardin, Dana B., Vaishampayan, Ulka N., Kato, Shumei, Grossman, Steven R., Glazer, Peter M., Shyr, Yu, Ivy, S. Percy, LoRusso, Patricia M.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2021
Teme:
Clinical Trial Results
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8265343/
https://ncbi.nlm.nih.gov/pubmed/33742489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13758
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items